TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05509348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: ADAPT Workshop
Description: 2 day workshop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: ADAPT Online
Description: Online curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: ADAPT Group
Description: 3 in person group sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: ADAPT Individual
Description: 3 sessions in person one on one
Study: NCT02004158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Study: NCT02056938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulins treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab treatment
Study: NCT01190319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Beverage
Description: Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo beverage, 8 weeks
Study: NCT01225952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crystalens AO
Description: Bausch \& Lomb model silicone multi-piece accommodating IOL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR 3.0
Description: An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Tecnis Multifocal
Description: The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
Study: NCT05058326

Intervention type: DIAGNOSTIC_TEST
Intervention: Portable endoanal manometry
Description: Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoanal ultrasound
Description: To assess the integrity of the anal canal.

Intervention type: OTHER
Intervention: Incontinence severity scale questionaires
Description: Wexner and St. Mark's scales.
Study: NCT02932202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal Nutritional Counseling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Study: NCT03892070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)
Description: 1.5 g of HMB will be provided for 12 weeks twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: 1.5 g twice daily for 12 weeks
Study: NCT00006111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT01967186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal islet transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular islet transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular transpl with stemcells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm
Study: NCT02529696

Intervention type: DEVICE
Intervention: Accelerometer
Description: Measures patient movement
Study: NCT02806518

Intervention type: PROCEDURE
Intervention: DIRT
Description: An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
Study: NCT04663464

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Description: Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Description: Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-SC
Description: Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-SC
Description: Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
Study: NCT00888108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
Study: NCT00015990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02932709

Intervention type: BEHAVIORAL
Intervention: suicide attempt
Description: suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
Study: NCT03510091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
Study: NCT01807546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
Study: NCT01820195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral N-Acetyl Cystein
Description: Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV N-Acetyl Cystein
Description: Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The patients in this group will be received both oral placebo and IV placebo
Study: NCT02131324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06 Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate Cream 0.05%
Study: NCT01424332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral
Study: NCT04753099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupation-based coaching
Description: Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2).
Study: NCT04091425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 placebo-matching IV infusion
Study: NCT03636919

Intervention type: OTHER
Intervention: e-BOOK
Description: Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
Study: NCT04184336

Intervention type: OTHER
Intervention: surveillance
Study: NCT03019770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Decision Aid
Description: All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
Study: NCT02779192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 200mg
Description: Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 400mg
Description: Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
Study: NCT04156412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant test procedure
Description: Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
Study: NCT02779192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
Study: NCT03360175

Intervention type: OTHER
Intervention: No intervention - observational study
Description: No intervention - observational study
Study: NCT02641002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90002
Description: Monoclonal Ab to CD47
Study: NCT01613378

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT00269581

Intervention type: OTHER
Group type: OTHER
Intervention: Educational CD-rom
Description: Educational CD-Rom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headstrong CD-rom
Description: Headstrong CD-rom
Study: NCT00708708

Intervention type: DRUG
Intervention: etanercept (Enbrel®)
Description: The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT01056640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intel Health Guide
Description: The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care intervention will include appropriate primary care and specialty office practice visits as required.
Study: NCT04396743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with use of prf-high clot and membrane
Description: Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with use of prf-medium clot and membrane
Description: Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
Study: NCT00903019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Problem-Solving Therapy
Description: Six sessions of tele-PST

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person PST
Description: Six sessions of in person PST

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Six weekly telephone calls
Study: NCT01012388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
Study: NCT01691963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)
Description: Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position.
Study: NCT04675944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: 200 mg (2 x 100 mg tablets), oral route
Study: NCT02291692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral blockade
Description: ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
Study: NCT02736292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practices for Healthcare Professionals
Study: NCT04273282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexycu intracameral dexamethasone
Description: To evaluate the safety and ocular efficacy of Dexycu.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
Study: NCT00006111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT00099359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Description: Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epivir (3TC)
Description: Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Description: 200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
Study: NCT01337531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-F, Fostimon
Description: dosage form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F, Fostimon
Description: injection, daily, 10-15 days
Study: NCT01144078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Intensity Exercise
Description: The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
Study: NCT04675944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: 1 mg (1 extended-release tablet), oral route
Study: NCT03506373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT04593342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Cure Pro
Description: The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
Study: NCT02227459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Study: NCT01144078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
Study: NCT03907514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FALE Application
Description: FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care.
Study: NCT04913207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: method of device size selection
Description: device size selection based on 3D-CTA

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: method of device size selection
Description: device size selection based on 3D-CTA
Study: NCT01468376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-01
Description: 14 day dosing
Study: NCT04374110

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical characteristics from medical records

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical characteristics from medical records
Study: NCT04373200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples collection
Description: Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples collection
Description: Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva collection at Month 4 for 25 survivors COVID-19 patients
Study: NCT03506373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study: NCT04373200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection at Month 4 for 25 survivors COVID-19 patients
Study: NCT02059447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment waiting period
Description: All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment waiting period
Description: All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Study: NCT02589821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study: NCT03719131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Receive standard of care nivolumab therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Receive standard of care nivolumab therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given IV or SC
Study: NCT00006111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery